帕博利珠单抗单药治疗经治晚期高度微卫星不稳定/错配修复缺陷子宫内膜癌患者健康相关生活质量:KEYNOTE-158研究
KEYNOTE-158多队列2期研究纳入经治晚期MSI-H/dMMR子宫内膜癌患者,接受帕博利珠单抗200 mg每3周一次共35个周期。84例可分析患者中,QLQ-C30总体健康状况/生活质量评分从基线至第9周平均改善6.08分(95%CI 0.71-11.46),达到完全或部分缓解者改善11.67分(95%CI 5.33-18.00)。
要点
- 帕博利珠单抗治疗期间及停药后30天评估健康相关生活质量。
- 总体人群QLQ-C30总体健康状况/生活质量评分第9周较基线平均改善6.08分。
- 达到完全或部分缓解者QLQ-C30评分改善幅度更大,为11.67分。
核心结论
- 帕博利珠单抗维持或改善了经治晚期MSI-H/dMMR子宫内膜癌患者的健康相关生活质量,进一步支持KEYNOTE-158的疗效与安全性结果及帕博利珠单抗在该场景的应用。
研究设计与样本
- 多队列2期KEYNOTE-158研究(ClinicalTrials.gov,NCT02628067)分析队列D(任何MSI状态的子宫内膜癌)和队列K(除结直肠癌外的任何MSI-H/dMMR实体瘤)中经治晚期MSI-H/dMMR子宫内膜癌患者。
- 患者接受帕博利珠单抗200 mg每3周一次共35个周期。
- 90例入组患者中84例完成至少1份健康相关生活质量问卷并纳入分析。
- 使用EORTC QLQ-C30和EQ-5D-3L问卷,在基线、治疗期间定期及停药后30天评估。
- 预设探索性分析包括所有患者及按最佳总体缓解分组的QLQ-C30总体健康状况/生活质量及EQ-5D-3L视觉模拟量表评分从基线至第9周的变化。
主要发现
- QLQ-C30和EQ-5D-3L基线依从率分别为90%和94%,第9周分别为92%和93%。
- 总体人群QLQ-C30总体健康状况/生活质量评分从基线至第9周平均改善6.08分(95%CI 0.71-11.46)。
- 达到完全或部分缓解的患者QLQ-C30总体健康状况/生活质量评分平均改善11.67分(95%CI 5.33-18.00)。
- 总体人群EQ-5D-3L视觉模拟量表评分平均改善6.00分(95%CI 2.25-9.75)。
- 达到完全或部分缓解的患者EQ-5D-3L视觉模拟量表评分平均改善9.11分(95%CI 5.24-12.98)。
临床怎么用
- 帕博利珠单抗200 mg每3周一次共35个周期用于经治晚期MSI-H/dMMR子宫内膜癌患者时,健康相关生活质量维持或改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pembrolizumab demonstrated a clinically meaningful objective response rate in patients with previously treated, advanced MSI-H/dMMR endometrial cancer in the multicohort phase 2 KEYNOTE-158 study (ClinicalTrials.gov, NCT02628067). We present health-related quality of life (HRQoL) results for these patients. METHODS: This analysis included patients from cohorts D (endometrial cancer with any MSI status) and K (any MSI-H/dMMR solid tumor except colorectal) who had previously treated, advanced MSI-H/dMMR endometrial cancer. Patients received pembrolizumab 200 mg Q3W for 35 cycles. EORTC QLQ-C30 and EQ-5D-3L questionnaires were administered at baseline, at regular intervals during treatment, and 30 days after treatment discontinuation. Pre-specified exploratory analyses included changes from baseline to week 9 in QLQ-C30 global health status (GHS)/QoL and EQ-5D-3L visual analog scale (VAS) score for all patients and by best overall response. RESULTS: 84 of 90 enrolled patients completed ≥1 HRQoL questionnaire and were included in the analysis. QLQ-C30 and EQ-5D-3L compliance rates were 90% and 94%, respectively, at baseline, and 92% and 93% at week 9. Mean (95% CI) QLQ-C30 GHS/QoL scores improved from baseline to week 9 by 6.08 (0.71-11.46) points in the overall population, with greater improvement in patients who achieved complete or partial response (11.67 [5.33-18.00]-point increase). Mean (95% CI) EQ-5D-3L VAS scores improved by 6.00 (2.25-9.75) points in the overall population and 9.11 (5.24-12.98) points in patients with CR/PR. CONCLUSIONS: Pembrolizumab maintained or improved HRQoL in patients with previously treated, advanced MSI-H/dMMR endometrial cancer, further supporting efficacy and safety results from KEYNOTE-158 and pembrolizumab use in this setting.
引用
- O'Malley DM, Bariani GM, Cassier PA, et al. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecol Oncol. 2022. PMID: 35835611. doi:10.1016/j.ygyno.2022.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。